One main goal of anti-cancer therapies is to kill tumor cells without affecting the surrounding normal cells. Therefore, many drugs are designed to target tumor-specific antigens, which are molecules ...

A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified ...

In a recent article published in Nature Cancer, a multi-institutional research team led by The University of Osaka describes ...

The first patient with relapsed or refractory acute myeloid leukemia has been dosed with Annamycin plus Cytarabine in the ...

Ava Salonia, who played with the Oceanside Sailors, died at age 16 following a nearly 12-month battle with acute myeloid ...

Scientists have identified a promising new drug target for acute myeloid leukemia, a deadly blood cancer with a five-year ...

Akriti Jain, MD, discussed how emerging data on non-ABL1 mutations is reshaping chronic myeloid leukemia management.

A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified a promising new drug target for acute myeloid leukemia (AML), a deadly ...

The start of patient dosing represents a huge milestone for Moleculin and, importantly, the AML community. “Our team rem ...